Canada - English - Health Canada

grifols therapeutics llc - albumin (human) - solution - 5% - albumin (human) 5% - blood derivatives

Canada - English - Health Canada

grifols therapeutics llc - albumin (human) - solution - 25% - albumin (human) 25% - blood derivatives

United States - English - NLM (National Library of Medicine)

csl behring llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 25 g in 100 ml - albumin is indicated in the emergency treatment of shock and in other similar conditions where the restoration of blood volume is urgent. if there has been considerable loss of red blood cells, transfusion with packed red blood cells is indicated. albumin or albumin in either normal saline or dextrose is indicated to prevent marked hemoconcentration and to maintain appropriate electrolyte balance. albumin is indicated in those clinical situations usually associated with a low concentration of plasma protein and a resulting decreased circulating blood volume. although diuresis may occur soon after albumin administration has been instituted, best results are obtained if albumin is continued until the normal serum protein level is regained. albuminar® -25 may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

grifols malaysia sdn. bhd. - albumin (human), usp -

Malta - English - Medicines Authority

kedrion s.p.a loc. ai conti, 55051 castelvecchio pascoli, barga - lucca, italy - albumin, human - solution for infusion - albumin, human 20 g/100ml - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - albumin, human - solution for infusion - albumin, human 4.5 percent weight/volume - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - albumin, human - solution for infusion - albumin, human 20 percent weight/volume - blood substitutes and perfusion solutions

New Zealand - English - Ministry for Primary Industries

envirofume limited - aluminium phosphide - aluminium phosphide 570 g/kg - insecticide

United States - English - NLM (National Library of Medicine)

csl behring ag - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 12.5 g in 250 ml - the definitive treatment of major hemorrhage is the transfusion of red blood cells restoring a normal oxygen transport capacity of the blood. since, however, the life-threatening event in major hemorrhage is the loss of blood volume and not the erythrocyte deficit, the blood volume can, as an emergency measure, be supported by alburx® 5, albumin (human) 5% solution or another rapidly acting plasma substitute if blood is not immediately available. this will restore cardiac output and abolish circulatory failure with tissue anoxia. though a four- to fivefold volume of crystalloids may be equally effective, their administration takes more time and creates a general overload with sodium and water. in the presence of dehydration, electrolyte solutions such as ringer's lactate should be administered in conjunction with albumin. apart from damage to the respiratory tract, the development of burn shock is the most life-threatening event in the immediate care of the burned patient. therapy during the first 24 hours i

United States - English - NLM (National Library of Medicine)

jubilant draximage inc - albumin aggregated (unii: 799c8vf17r) (albumin aggregated - unii:799c8vf17r) - albumin aggregated 2.5 mg - draximage maa, after radiolabeling with sodium pertechnetate tc 99m, is indicated for: - lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. - peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adult patients. draximage maa is contraindicated in patients with: - severe pulmonary hypertension [see warnings and precautions (5.1)]. - a history of hypersensitivity to albumin human.reactions have included anaphylaxis [see warnings and precautions (5.2)] . risk summary   available data with technetium tc 99m albumin aggregated injection use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects and miscarriage. animal reproduction studies with technetium tc 99m albumin aggregated have not been conducted radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. the radiation exposure to the fetus from technetium tc 99m albumin aggregated is expected to be low (less than 0.5 mgy) (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. data human data no adverse fetal effects of radiation risks have been identified for diagnostic procedures involving less than 50 mgy, which represents less than 10 mgy fetal doses. risk summary technetium-99m is present in breast milk. there are no data on the effects of technetium tc 99m albumin aggregated on the breastfed infant or the effects on milk production. draximage maa is used for imaging in infants with lung disease; exposure to technetium-99m via breastmilk is expected to be lower. based on clinical guidelines, exposure of technetium tc 99m albumin aggregated to a breastfed infant may be minimized by advising a lactating woman to temporarily discontinue breastfeeding and to pump and discard breast milk for a minimum of at least 24 hours after administration of technetium tc 99m albumin aggregated injection. the developmental and health benefits of breastfeeding should be considered along with a mother’s clinical need for draximage maa, any potential adverse effects on the breastfed child from technetium tc 99m albumin aggregated or from the underlying maternal condition. draximage maa, after radiolabeling with technetium-99m, is indicated for lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in pediatric patients (birth to less than 17 years of age). the safety profile of technetium tc 99m albumin aggregated injection in pediatric patients is similar to adults. the safety and efficacy of draximage maa have not been established for peritoneovenous shunt scintigraphy in pediatric patients.  no formal studies of draximage maa in subjects aged 65 and over were performed to determine whether they respond differently from younger adult subjects. other reported clinical experience has not identified differences in responses between the elderly and younger adult patients. in general, dose selection for an elderly patient should be cautious; administering the low end of the particle dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.